Beckman Coulter and Fujirebio enter into partnership
The goal is a patient-friendly, blood-based Alzheimer's disease test
22-Sep-2023 -
Beckman Coulter Diagnostics and Fujirebio announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.
The burden of disability and deaths ...
Alzheimer's disease
biomarker
dementia
+2